These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 11870014)

  • 1. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?
    Zimmerman M; Mattia JI; Posternak MA
    Am J Psychiatry; 2002 Mar; 159(3):469-73. PubMed ID: 11870014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included.
    Zimmerman M; Chelminski I; Posternak MA
    J Nerv Ment Dis; 2004 Feb; 192(2):87-94. PubMed ID: 14770052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial.
    Zimmerman M; Chelminski I; Posternak MA
    Am J Psychiatry; 2005 Jul; 162(7):1370-2. PubMed ID: 15994721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of exclusion criteria in antidepressant clinical trials: a replication study.
    Zetin M; Hoepner CT
    J Clin Psychopharmacol; 2007 Jun; 27(3):295-301. PubMed ID: 17502778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice.
    van der Lem R; van der Wee NJ; van Veen T; Zitman FG
    Psychol Med; 2011 Jul; 41(7):1353-63. PubMed ID: 21078225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reevaluation of the exclusion criteria used in antidepressant efficacy trials.
    Posternak MA; Zimmerman M; Keitner GI; Miller IW
    Am J Psychiatry; 2002 Feb; 159(2):191-200. PubMed ID: 11823258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS; Benazzi F; Perugi G; Rihmer Z
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years.
    Zimmerman M; Holst CG; Clark HL; Multach M; Walsh E; Rosenstein LK; Gazarian D
    CNS Drugs; 2016 Dec; 30(12):1209-1218. PubMed ID: 27541608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bipolar depression in a low-income primary care clinic.
    Olfson M; Das AK; Gameroff MJ; Pilowsky D; Feder A; Gross R; Lantigua R; Shea S; Weissman MM
    Am J Psychiatry; 2005 Nov; 162(11):2146-51. PubMed ID: 16263856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An illustration of how a self-report diagnostic screening scale could improve the internal validity of antidepressant efficacy trials.
    Zimmerman M; Chelminski I; Posternak M
    J Affect Disord; 2004 May; 80(1):79-85. PubMed ID: 15094261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Have Treatment Studies of Depression Become Even Less Generalizable? Applying the Inclusion and Exclusion Criteria in Placebo-Controlled Antidepressant Efficacy Trials Published over 20 Years to a Clinical Sample.
    Zimmerman M; Balling C; Chelminski I; Dalrymple K
    Psychother Psychosom; 2019; 88(3):165-170. PubMed ID: 31096246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptom severity and exclusion from antidepressant efficacy trials.
    Zimmerman M; Posternak MA; Chelminski I
    J Clin Psychopharmacol; 2002 Dec; 22(6):610-4. PubMed ID: 12454561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the medical outcomes study.
    Wells KB; Katon W; Rogers B; Camp P
    Am J Psychiatry; 1994 May; 151(5):694-700. PubMed ID: 7909411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Commonly Used Inclusion and Exclusion Criteria in Antidepressant Registration Trials Affect Study Enrollment.
    Preskorn SH; Macaluso M; Trivedi M
    J Psychiatr Pract; 2015 Jul; 21(4):267-74. PubMed ID: 26164052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic.
    Glezer A; Byatt N; Cook R; Rothschild AJ
    J Affect Disord; 2009 Sep; 117(1-2):18-23. PubMed ID: 19103462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inclusion/exclusion criteria in late life depression antidepressant efficacy trials.
    Zimmerman M; Multach MD; Clark HL; Walsh E; Rosenstein LK; Gazarian D
    Int J Geriatr Psychiatry; 2017 Sep; 32(9):1009-1016. PubMed ID: 27546477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients excluded from an antidepressant efficacy trial.
    Partonen T; Sihvo S; Lönnqvist JK
    J Clin Psychiatry; 1996 Dec; 57(12):572-5. PubMed ID: 9010119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antidepressants consumption in the global population in France].
    Olié JP; Elomari F; Spadone C; Lépine JP
    Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.